Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

John Moroney

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentObstetrics & Gynecology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    John Moroney, MD, specializes in the diagnosis and treatment of gynecologic cancers, with a focus on providing skilled and personalized longitudinal care. He believes that access to innovative surgical techniques and targeted medical therapies are essential in achieving optimal outcomes.

    Dr. Moroney is the principal investigator (PI) at the University of Chicago for NRG Oncology, a National Cancer Institute-supported clinical trials cooperative group. He also serves as the PI for numerous other industry-sponsored clinical trials.


    Collapse Biography 
    Collapse education and training
    Loyola University Stritch School of MedicineMD
    Walter Reed National Military Medical CenterInternship
    Walter Reed National Military Medical CenterResidency
    MD Anderson Cancer CenterFellowship

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Luke JJ, Onderdonk BE, Bhave SR, Karrison T, Lemons JM, Chang P, Zha Y, Carll T, Krausz T, Huang L, Martinez CA, Janisch LA, Hseu R, Moroney JW, Patel JD, Khodarev NN, Salama JK, Ott PA, Fleming GF, Gajewski TF, Weichselbaum RR, Pitroda SP, Chmura SJ. Improved survival associated with local tumor response following multi-site radiotherapy and pembrolizumab: secondary analysis of a phase I trial. Clin Cancer Res. 2020 Oct 07. PMID: 33028595.
      View in: PubMed
    2. Moroney JW, Powderly J, Lieu CH, Bendell JC, Eckhardt SG, Chang CW, Molinero L, Spahn J, Williams P, Lin YG, Hodi FS. Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study. Clin Cancer Res. 2020 Jul 28. PMID: 32723836.
      View in: PubMed
    3. Kurnit KC, Reid P, Moroney JW, Fleming GF. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. Gynecol Oncol. 2020 Sep; 158(3):531-537. PMID: 32641238.
      View in: PubMed
    4. Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Jun 13. PMID: 31194228.
      View in: PubMed
    5. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019 07; 69(4):258-279. PMID: 31074865.
      View in: PubMed
    6. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618. PMID: 29437535.
      View in: PubMed
    7. Son CH, Fleming GF, Moroney JW. Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. Cancer Manag Res. 2017; 9:553-563. PMID: 29184441.
      View in: PubMed
    8. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, Hong D, Naing A, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805. PMID: 22927482.
      View in: PubMed
    9. Moroney JW, Schlumbrecht MP, Helgason T, Coleman RL, Moulder S, Naing A, Bodurka DC, Janku F, Hong DS, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6. PMID: 21890452.
      View in: PubMed
    10. Moulder S, Moroney J, Helgason T, Wheler J, Booser D, Albarracin C, Morrow PK, Koenig K, Kurzrock R. Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):e572-5. PMID: 21482991.
      View in: PubMed
    11. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. . 2011 Mar; 10(3):558-65. PMID: 21216929.
      View in: PubMed
    12. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, Lu K, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. Gynecol Oncol. 2010 Jun; 117(3):467-72. PMID: 20347123.
      View in: PubMed
    13. Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother. 2009 Nov; 21(5):566-72. PMID: 19933049.
      View in: PubMed
    14. Frumovitz M, Soliman PT, Greer M, Schmeler KM, Moroney J, Bodurka DC, Ramirez PT. Laparoscopy training in gynecologic oncology fellowship programs. Gynecol Oncol. 2008 Nov; 111(2):197-201. PMID: 18804849.
      View in: PubMed
    15. Moroney JW, Zahn CM, Heaton RB, Crothers B, Kendall BS, Elkas JC. Normal endometrial cells in liquid-based cervical cytology specimens in women aged 40 or older. Gynecol Oncol. 2007 Jun; 105(3):672-6. PMID: 17363044.
      View in: PubMed
    Moroney's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _